


Figure S1. Utilization pattern of glucose-lowering agents among type 2 diabetes patients with advanced chronic kidney disease (stage 3b-5) in 2011-2016



Abbreviations: CKD, chronic kidney disease; GLA, glucose-lowering agent; DPP4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.

## Notes

- (1) The results were based on the data from Taiwan's National Health Insurance Research database (NHIRD) 2010-2016. The study drug users were identified from year 2011-2015 in the NHIRD and each of them was given one-year baseline period and at least one-year follow-up period.
- (2) Patients with CKD stage 3b-5 were confirmed by the status of enrollment in a nationwide pre-end-stage renal disease (pre-ESRD) care program in Taiwan.